Relevant factors | With hepatic dysfunction (n (%)) | Without hepatic dysfunction (n (%)) | B | OR value | 95% CI | P value | |
Age | ≤45 >45 | 350 (68.50) 331 (68.25) | 161 (31.50) 154 (31.75) | −1.011 | 1 1.011 | 0.744 to 1.321 | 0.934 |
Sex | Male Female | 158 (50.97) 523 (76.24) | 152 (49.03) 163 (23.76) | −1.127 | 1 0.324 | 0.244 to 0.430 | 0.000 |
Time between thyroidectomy and 131I therapy | ≤3 months >3 months | 560 (68.20) 121 (69.14) | 261 (31.80) 54 (30.86) | 0.043 | 1 1.044 | 0.734 to 1.486 | 0.810 |
Thyroid hormone withdrawal time | ≤21 days >21 days | 372 (72.51) 309 (63.98) | 141 (27.49) 174 (36.02) | 0.396 | 1 1.486 | 0.517 to 0.892 | 0.005 |
Metastases | Negative Positive | 152 (72.38) 529 (67.30) | 58 (27.62) 257 (32.70) | −0.242 | 1 0.785 | 0.561 to 1.100 | 0.160 |
Hashimoto’s thyroiditis | Negative Positive | 595 (67.85) 86 (72.27) | 282 (32.15) 33 (27.73) | −0.211 | 1 0.810 | 0.529 to 1.239 | 0.331 |
FT3 | <2.01* ≥2.01 | 316 (63.71) 365 (73.00) | 180 (36.29) 135 (27.00) | 0.432 | 1 1.540 | 1.177 to 2.016 | 0.002 |
FT4 | <4.78* ≥4.78 | 280 (56.34) 401 (80.36) | 217 (43.66) 98 (19.64) | 1.154 | 1 3.171 | 2.389 to 4.209 | 0.000 |
TSH | <78.195* ≥78.195 | 365 (73.29) 316 (63.45) | 133 (26.71) 182 (36.55) | −0.458 | 1 0.633 | 0.483 to 0.828 | 0.001 |
Tg | <2.635* ≥2.635 | 346 (69.48) 335 (67.27) | 152 (30.52) 163 (32.73) | −0.185 | 1 0.831 | 0.609 to 1.134 | 0.244 |
TgAb | ≤40† >40 | 527 (66.96) 154 (73.68) | 260 (33.04) 55 (26.32) | 0.381 | 1 1.374 | 0.979 to 1.930 | 0.067 |
TC | ≤5.17† >5.17 | 129 (75.44) 552 (66.90) | 42 (24.56) 273 (33.10) | 0.758 | 1 2.135 | 1.615 to 2.822 | 0.000 |
TG | ≤1.71† >1.71 | 336 (77.42) 344 (61.54) | 98 (22.58) 215 (38.46) | −0.418 | 1 0.658 | 0.451 to 0.960 | 0.03 |
*Median.
†Upper limit of the normal value.
DTC, differentiated thyroid cancer; FT3, free triiodothyronine; FT4, free thyroxine; TC, total cholesterol; Tg, thyroglobulin; TG, triglycerides; TgAb, antithyroglobulin antibody; TSH, thyroid-stimulating hormone.